We waited years for working RSV vaccines and in 2023, in the space of just a few weeks, we had two come all at once, with another on the horizon and a fresh approval for an RSV prevention med.
But how will the RSV market shake out? Well, the analysts at GlobalData crunched the numbers and forecast that GSK’s Arexvy will be the market leader.
Analysts at the firm see the total RSV market hitting $9 billion by 2029, up from the $1 billion expected this year, and Arexvy is projected to “climb steadily and emerge as a market leader,” the firm said in its latest report.
Over this seven-year forecast, GlobalData reckons GSK’s shot will generate more than a quarter of that total global RSV market, with just over $2.5 billion in sales by 2029.
Arexvy was the first-ever RSV vaccine to gain an approval, getting a yes from the FDA back in May and swiftly followed with an EU green light, something that will help boost its overall sales trajectory.
Pfizer’s rival RSV vaccine Abrysvo, which is yet to nab European approval, got its FDA approval mere weeks after GSK, but is set to make just $1.7 billion over the same period.
That would put in an unexpected third place, behind an RSV vaccine that isn’t even approved yet: namely, Moderna’s mRNA-1345.